Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis

Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance th...

Full description

Saved in:
Bibliographic Details
Published inArthritis research & therapy Vol. 11; no. 5; p. R149
Main Authors Nanki, Toshihiro, Takada, Kazuki, Komano, Yukiko, Morio, Tomohiro, Kanegane, Hirokazu, Nakajima, Atsuo, Lipsky, Peter E, Miyasaka, Nobuyuki
Format Journal Article
LanguageEnglish
Published London BioMed Central 01.01.2009
BioMed Central Ltd
National Library of Medicine - MEDLINE Abstracts
Subjects
Online AccessGet full text
ISSN1478-6354
1478-6362
1478-6354
1478-6362
DOI10.1186/ar2823

Cover

Abstract Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation. Methods Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by 3 H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay. Results Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27 + than CD27 - peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27 + B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor. Conclusions The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium.
AbstractList INTRODUCTION: Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation. METHODS: Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by 3H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay. RESULTS: Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27+ than CD27- peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27+ B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor. CONCLUSIONS: The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium.
Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation. Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by 3H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay. Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27+ than CD27- peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27+ B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor. The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium.
Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation. Methods Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by .sup.3.sup.H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay. Results Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27.sup.+ .sup.than CD27.sup.- .sup.peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27.sup.+ .sup.B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor. Conclusions The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium.
Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation. Methods Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by 3 H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay. Results Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27 + than CD27 - peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27 + B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor. Conclusions The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium.
Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation.INTRODUCTIONAccumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the pathogenesis of RA by antigen presentation, autoantibody production, and/or inflammatory cytokine production. Chemokines could enhance the accumulation of B cells in the synovium. The aims of this study were to determine chemokine receptor expression by B cells both in the peripheral blood of normal donors and subjects with RA, and at the inflammatory site in RA, and the effects of chemokines on B cell activation.Cell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by 3H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay.METHODSCell surface molecule expression was analyzed by flow cytometry. Cellular migration was assessed using chemotaxis chambers. Cellular proliferation was examined by 3H-thymidine incorporation. Tumor necrosis factor (TNF) production was assayed by enzyme-linked immunosorbent assay.Significant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27+ than CD27- peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27+ B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor.RESULTSSignificant numbers of peripheral blood B cells of healthy donors and subjects with RA expressed CC chemokine receptor (CCR)5 and CXCR3, and most B cells expressed CCR6, CCR7, CXCR4 and CXCR5. CCR5 expression was more frequent on CD27+ than CD27- peripheral blood B cells of healthy donors and RA. Synovial B cells more frequently expressed CCR5, but less often expressed CCR6, CCR7 and CXCR5 compared to peripheral blood in RA. Further functional analyses were performed on peripheral blood B cells from healthy donors. Migration of peripheral blood B cells, especially CD27+ B cells, was enhanced by CC chemokine ligand (CCL)20, CCL19, CCL21 and CXCL12. All four chemokines alone induced B cell proliferation; with CCL21 being the most effective. CCL21 also enhanced the proliferation of anti-immunoglobulin (Ig)M-stimulated B cells and blockade of CCR7 inhibited this effect. CCL20, CCL21 and CXCL12 enhanced TNF production by anti-IgM mAb-stimulated B cells. Finally, stimulation with CXCL12, but not CCL20, CCL19 and CCL21, enhanced inducible costimulator-ligand (ICOSL) expression by peripheral blood B cells of healthy donors and RA, but did not increase B cell-activating factor receptor or transmembrane activator and CAML-interactor.The data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium.CONCLUSIONSThe data suggest that CCR5, CCR6, CCR7, CXCR3, CXCR4 and CXCR5 may be important for the B cell migration into the synovium of RA patients, and also their local proliferation, cytokine production and ICOSL expression in the synovium.
ArticleNumber R149
Audience Academic
Author Lipsky, Peter E
Kanegane, Hirokazu
Komano, Yukiko
Nanki, Toshihiro
Miyasaka, Nobuyuki
Takada, Kazuki
Morio, Tomohiro
Nakajima, Atsuo
AuthorAffiliation 1 Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
3 Department of Pediatrics and Developmental Biology, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
2 Department of Pharmacovigilance, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
5 Department of Joint Disease and Rheumatism, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan
4 Department of Pediatrics, Graduate School of Medicine, University of Toyama, 2630, Sugitani, Toyama, 930-0194, Japan
8 Global Center of Excellence (GCOE) Program; International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
7 National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 90
AuthorAffiliation_xml – name: 6 Department of Rheumatology, Tokyo Metropolitan Police Hospital, 4-22-1, Nakano, Nakano-ku, Tokyo, 164-8541, Japan
– name: 8 Global Center of Excellence (GCOE) Program; International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
– name: 3 Department of Pediatrics and Developmental Biology, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
– name: 5 Department of Joint Disease and Rheumatism, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan
– name: 7 National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
– name: 1 Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
– name: 2 Department of Pharmacovigilance, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
– name: 4 Department of Pediatrics, Graduate School of Medicine, University of Toyama, 2630, Sugitani, Toyama, 930-0194, Japan
Author_xml – sequence: 1
  givenname: Toshihiro
  surname: Nanki
  fullname: Nanki, Toshihiro
  email: nanki.rheu@tmd.ac.jp
  organization: Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, Department of Pharmacovigilance, Graduate School, Tokyo Medical and Dental University
– sequence: 2
  givenname: Kazuki
  surname: Takada
  fullname: Takada, Kazuki
  organization: Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University
– sequence: 3
  givenname: Yukiko
  surname: Komano
  fullname: Komano, Yukiko
  organization: Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, Department of Pharmacovigilance, Graduate School, Tokyo Medical and Dental University
– sequence: 4
  givenname: Tomohiro
  surname: Morio
  fullname: Morio, Tomohiro
  organization: Department of Pediatrics and Developmental Biology, Graduate School, Tokyo Medical and Dental University
– sequence: 5
  givenname: Hirokazu
  surname: Kanegane
  fullname: Kanegane, Hirokazu
  organization: Department of Pediatrics, Graduate School of Medicine, University of Toyama
– sequence: 6
  givenname: Atsuo
  surname: Nakajima
  fullname: Nakajima, Atsuo
  organization: Department of Joint Disease and Rheumatism, Nippon Medical School, Department of Rheumatology, Tokyo Metropolitan Police Hospital
– sequence: 7
  givenname: Peter E
  surname: Lipsky
  fullname: Lipsky, Peter E
  organization: National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health
– sequence: 8
  givenname: Nobuyuki
  surname: Miyasaka
  fullname: Miyasaka, Nobuyuki
  organization: Departments of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, Global Center of Excellence (GCOE) Program; International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19804625$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAQxyNURB_AR0AWB7iwxa_YDgeksuIlVeIC58hxJhuXxA62g-AL8Llxulu2XQTywR7Pb_6eGc9pceS8g6J4TPA5IUq81IEqyu4VJ4RLtRKs5Ee3zsfFaYxXGFNaUf6gOCaVwlzQ8qT4te5h9F-tAxTAwJR8QPBjChCj9Q5p16JudiZlQw8Iug5Mish3yNzEZcuhN8jAMMRXyI7TYI1eeGQdSj2gSafebyCT9joy9DCPOnnbIh1SH2yy8WFxv9NDhEe7_az48u7t5_WH1eWn9x_XF5erRhCcVkxwooDTSpGyrHhjpGC4aXWFQVRKY0Y4aM4kmKpTmpPGGAxSCEw16zST7Kx4vdWd5maE1oBLQQ_1FOyow8_aa1vf9Tjb1xv_vaZSSapEFqi2Ao31_xC46zF-rLefk2Of7x4P_tsMMdWjjUvftAM_x1oyTkpZCprJZ_8lKaGSCbyk8_QAvPJzyF-1MJKrSlKeofMttNED1NZ1Pmdm8mphtCbPUWfz_QUlGJeSi0X1ye0u_anuZmz2-ZngYwzQ7RFcL_O4L_nFAWhsup6OnIId_sZ3HYpZz20g7Ms5IH8DtkPxlg
CitedBy_id crossref_primary_10_1016_j_cellimm_2020_104263
crossref_primary_10_1038_icb_2010_158
crossref_primary_10_1016_j_jdsr_2019_09_006
crossref_primary_10_3109_13880209_2015_1074254
crossref_primary_10_1080_14397595_2017_1341458
crossref_primary_10_1016_j_rdc_2010_02_003
crossref_primary_10_1111_eci_12063
crossref_primary_10_1002_advs_202409537
crossref_primary_10_1002_art_38137
crossref_primary_10_4049_jimmunol_1001139
crossref_primary_10_1593_tlo_11115
crossref_primary_10_1111_ajt_13207
crossref_primary_10_1111_aji_13154
crossref_primary_10_1039_c2cs35085h
crossref_primary_10_3389_fimmu_2018_01707
crossref_primary_10_1016_j_heliyon_2024_e27861
crossref_primary_10_1016_j_imlet_2018_05_003
crossref_primary_10_1080_14397595_2016_1213481
crossref_primary_10_1002_advs_202308447
crossref_primary_10_1186_s43042_024_00550_1
crossref_primary_10_1038_emm_2017_100
crossref_primary_10_1038_s41598_020_71362_7
crossref_primary_10_1016_j_sjbs_2020_08_045
crossref_primary_10_1038_s41598_017_09150_z
crossref_primary_10_1111_cei_12065
crossref_primary_10_1016_j_jaut_2020_102526
crossref_primary_10_1038_s41408_018_0130_3
crossref_primary_10_1002_art_38023
crossref_primary_10_1016_j_dci_2014_07_008
crossref_primary_10_1155_2012_391567
crossref_primary_10_1093_rheumatology_kez175
crossref_primary_10_3109_03009742_2013_803149
crossref_primary_10_3389_fimmu_2023_1100869
crossref_primary_10_1038_s41584_019_0323_6
crossref_primary_10_1016_j_mcpro_2022_100258
crossref_primary_10_18632_oncotarget_8163
crossref_primary_10_3390_ijms20215287
crossref_primary_10_1016_j_imlet_2020_06_014
crossref_primary_10_1080_13880209_2022_2143533
crossref_primary_10_1126_scitranslmed_3005407
crossref_primary_10_2177_jsci_39_172
crossref_primary_10_3390_vaccines9101171
crossref_primary_10_1016_j_cyto_2013_05_020
crossref_primary_10_3899_jrheum_110049
crossref_primary_10_1111_imm_13840
crossref_primary_10_1186_ar3158
crossref_primary_10_2310_7290_2014_00041
crossref_primary_10_1007_s12016_015_8520_9
crossref_primary_10_1016_j_mehy_2024_111422
crossref_primary_10_1186_s13075_018_1611_2
crossref_primary_10_1007_s00018_023_04715_w
crossref_primary_10_3389_fimmu_2020_01913
crossref_primary_10_1111_j_1600_0897_2012_01167_x
crossref_primary_10_1038_icb_2013_97
crossref_primary_10_1155_2014_681678
crossref_primary_10_1007_s10067_017_3652_3
crossref_primary_10_1186_s13075_015_0561_1
crossref_primary_10_3389_fcell_2022_882017
crossref_primary_10_3389_fimmu_2018_01924
crossref_primary_10_1186_s13075_016_0978_1
crossref_primary_10_1089_dna_2011_1350
crossref_primary_10_1371_journal_pone_0058140
crossref_primary_10_1002_art_27650
crossref_primary_10_1016_j_clinthera_2018_04_016
crossref_primary_10_1161_ATVBAHA_124_321434
crossref_primary_10_1016_j_cellsig_2019_109395
crossref_primary_10_1186_s13075_016_0957_6
crossref_primary_10_1189_jlb_1010565
crossref_primary_10_1124_pr_113_007724
crossref_primary_10_2174_1570163816666191023103118
crossref_primary_10_1016_j_autrev_2011_06_010
crossref_primary_10_1016_j_bbamcr_2014_05_014
crossref_primary_10_2174_1381612827666211104154459
crossref_primary_10_1016_j_it_2014_12_006
crossref_primary_10_1142_S0218339013500174
crossref_primary_10_1016_j_intimp_2023_110530
crossref_primary_10_1155_2022_7719301
crossref_primary_10_3389_fcimb_2019_00280
crossref_primary_10_1038_nrrheum_2010_68
crossref_primary_10_3390_pathophysiology31030038
crossref_primary_10_1016_j_yexcr_2010_12_017
crossref_primary_10_1016_j_jid_2019_07_717
crossref_primary_10_1186_s13075_016_1102_2
crossref_primary_10_1002_art_27767
crossref_primary_10_1016_j_jaut_2021_102684
crossref_primary_10_3389_fimmu_2022_907733
crossref_primary_10_1371_journal_pone_0101622
crossref_primary_10_3389_fimmu_2023_1331796
crossref_primary_10_3390_molecules24193591
crossref_primary_10_1182_blood_2016_08_735076
crossref_primary_10_1186_s13075_016_1065_3
Cites_doi 10.1038/sj.leu.2402107
10.1136/ard.51.9.1029
10.1002/art.1780350809
10.4049/jimmunol.165.11.6590
10.1038/16717
10.1002/art.21301
10.1006/cimm.2001.1890
10.1111/j.1365-2249.1995.tb03126.x
10.1002/art.22025
10.1016/S1074-7613(00)80165-X
10.1186/ar2107
10.4049/jimmunol.167.9.5381
10.1186/ar77
10.1016/S0065-2776(01)78002-9
10.1111/j.1365-2249.1994.tb06109.x
10.4049/jimmunol.168.10.5333
10.4049/jimmunol.148.10.3296
10.1016/j.cyto.2008.06.017
10.1186/ar2333
10.1007/s00296-004-0449-x
10.1186/ar2125
10.4049/jimmunol.170.12.6320
10.4049/jimmunol.166.1.650
10.1093/rheumatology/40.2.205
10.1097/01.LAB.0000062854.30195.52
10.1002/art.20932
10.1186/ar2718
10.1186/ar2200
10.1056/NEJM200011303432202
10.4049/jimmunol.172.6.3422
10.1182/blood.V95.2.627
10.1002/art.1780310302
10.1093/intimm/12.9.1285
10.4049/jimmunol.164.10.5010
10.4049/jimmunol.165.6.3423
10.1073/pnas.93.1.221
10.1016/j.berh.2006.06.001
10.1084/jem.173.2.487
ContentType Journal Article
Copyright Nanki et al.; licensee BioMed Central Ltd. 2009
COPYRIGHT 2009 BioMed Central Ltd.
Copyright National Library of Medicine - MEDLINE Abstracts 2009
Copyright ©2009 Nanki et al.; licensee BioMed Central Ltd. 2009 Nanki et al.; licensee BioMed Central Ltd.
Copyright_xml – notice: Nanki et al.; licensee BioMed Central Ltd. 2009
– notice: COPYRIGHT 2009 BioMed Central Ltd.
– notice: Copyright National Library of Medicine - MEDLINE Abstracts 2009
– notice: Copyright ©2009 Nanki et al.; licensee BioMed Central Ltd. 2009 Nanki et al.; licensee BioMed Central Ltd.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7QP
7T5
H94
7X8
5PM
DOI 10.1186/ar2823
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
AIDS and Cancer Research Abstracts
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList
ProQuest Health & Medical Complete (Alumni)
MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen Free (Free internet resource, activated by CARLI)
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1478-6354
1478-6362
EndPage R149
ExternalDocumentID PMC2787286
oai_biomedcentral_com_ar2823
1916818401
A210057466
19804625
10_1186_ar2823
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID ---
.GJ
0R~
23N
2WC
4.4
53G
5GY
5VS
6J9
AAFWJ
AAJSJ
AASML
ACGFS
ACJQM
ADBBV
ADUKV
AEGXH
AENEX
AFPKN
AHBYD
AHMBA
AHSBF
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
C1A
C6C
CS3
DIK
E3Z
EBLON
EJD
F5P
GROUPED_DOAJ
GX1
H13
HYE
HZ~
INH
INR
ITC
KQ8
O5R
O5S
O9-
PGMZT
PIMPY
PQQKQ
RBZ
ROL
RPM
RSV
SMD
SOJ
TR2
U2A
WOQ
AAYXX
ALIPV
CITATION
7X7
88E
8FI
8FJ
ABUWG
AFKRA
AHYZX
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
EBD
ECM
EIF
EMOBN
FYUFA
HMCUK
M1P
NPM
PHGZT
PROAC
PSQYO
SV3
UKHRP
ZGI
K9.
7QP
7T5
H94
7X8
-5E
-5G
-A0
-BR
3V.
ABVAZ
ACRMQ
ADINQ
AFGXO
AFNRJ
C24
IAO
IHR
Z7U
ZA5
5PM
ID FETCH-LOGICAL-b610t-36418e429815594bc7630bda90e698a0314ea437ec9f8a41bcc0e76602a3fa373
IEDL.DBID U2A
ISSN 1478-6354
1478-6362
IngestDate Thu Aug 21 14:05:41 EDT 2025
Wed May 22 07:11:13 EDT 2024
Thu Sep 04 23:56:40 EDT 2025
Thu Sep 04 15:53:09 EDT 2025
Mon Jun 30 16:54:52 EDT 2025
Tue Jun 10 21:24:42 EDT 2025
Thu Apr 03 07:09:50 EDT 2025
Tue Jul 01 04:00:29 EDT 2025
Thu Apr 24 22:58:33 EDT 2025
Sat Sep 06 07:28:13 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Rheumatoid Arthritis
Peripheral Blood CD27
Tumor Necrosis Factor Production
Synovial Tissue
Rheumatoid Arthritis Synovium
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b610t-36418e429815594bc7630bda90e698a0314ea437ec9f8a41bcc0e76602a3fa373
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://link.springer.com/10.1186/ar2823
PMID 19804625
PQID 217489724
PQPubID 42875
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2787286
biomedcentral_primary_oai_biomedcentral_com_ar2823
proquest_miscellaneous_734157562
proquest_miscellaneous_21273606
proquest_journals_217489724
gale_infotracacademiconefile_A210057466
pubmed_primary_19804625
crossref_primary_10_1186_ar2823
crossref_citationtrail_10_1186_ar2823
springer_journals_10_1186_ar2823
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-01-01
PublicationDateYYYYMMDD 2009-01-01
PublicationDate_xml – month: 01
  year: 2009
  text: 2009-01-01
  day: 01
PublicationDecade 2000
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Arthritis research & therapy
PublicationTitleAbbrev Arthritis Res Ther
PublicationTitleAlternate Arthritis Res Ther
PublicationYear 2009
Publisher BioMed Central
BioMed Central Ltd
National Library of Medicine - MEDLINE Abstracts
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: National Library of Medicine - MEDLINE Abstracts
References O Yoshie (2660_CR12) 2001; 78
MP Armengol (2660_CR18) 2003; 170
T Nanki (2660_CR38) 2001; 167
C Mauri (2660_CR6) 2007; 9
ME Duddy (2660_CR10) 2004; 172
T Jin (2660_CR13) 2008; 44
T Nanki (2660_CR36) 2000; 164
A Zlotnik (2660_CR11) 2000; 12
T Nanki (2660_CR35) 2005; 52
A Hutloff (2660_CR34) 1999; 397
SK Lundy (2660_CR3) 2007; 9
HJ Kim (2660_CR30) 2000; 2
D Jones (2660_CR19) 2000; 95
SK Lee (2660_CR31) 1992; 35
PE Lipsky (2660_CR33) 2000; 343
T Nanki (2660_CR28) 2000; 165
S Hosaka (2660_CR22) 1994; 97
K Shi (2660_CR29) 2001; 166
RW Kinne (2660_CR4) 2007; 9
SB Cohen (2660_CR2) 2006; 54
D van Zeben (2660_CR9) 1992; 51
G Page (2660_CR25) 2002; 168
E Robinson (2660_CR23) 1995; 101
A Ueno (2660_CR26) 2005; 25
FC Arnett (2660_CR16) 1988; 31
JH Ruth (2660_CR24) 2003; 83
V Lutzky (2660_CR5) 2007; 9
I Randen (2660_CR7) 1992; 148
PP Tak (2660_CR15) 2006; 20
AE Schroder (2660_CR32) 1996; 93
E Roosnek (2660_CR8) 1991; 173
AE Koch (2660_CR14) 2005; 52
CD Buckley (2660_CR27) 2000; 165
J Durig (2660_CR20) 2001; 15
MM Souto-Carneiro (2660_CR21) 2009; 11
T Nanki (2660_CR37) 2001; 214
M Brandes (2660_CR17) 2000; 12
JC Edwards (2660_CR1) 2001; 40
15004141 - J Immunol. 2004 Mar 15;172(6):3422-7
10799853 - J Immunol. 2000 May 15;164(10):5010-4
3358796 - Arthritis Rheum. 1988 Mar;31(3):315-24
10627472 - Blood. 2000 Jan 15;95(2):627-32
12794165 - J Immunol. 2003 Jun 15;170(12):6320-8
16980215 - Best Pract Res Clin Rheumatol. 2006 Oct;20(5):929-39
10714678 - Immunity. 2000 Feb;12(2):121-7
17850683 - Arthritis Res Ther. 2007;9(4):219
12695561 - Lab Invest. 2003 Apr;83(4):579-88
16947627 - Arthritis Rheum. 2006 Sep;54(9):2793-806
9930702 - Nature. 1999 Jan 21;397(6716):263-6
15004722 - Rheumatol Int. 2005 Jun;25(5):361-7
11086103 - J Immunol. 2000 Dec 1;165(11):6590-8
1578151 - J Immunol. 1992 May 15;148(10):3296-301
11096166 - N Engl J Med. 2000 Nov 30;343(22):1594-602
1703209 - J Exp Med. 1991 Feb 1;173(2):487-9
17349064 - Arthritis Res Ther. 2007;9(2):205
11994492 - J Immunol. 2002 May 15;168(10):5333-41
7545093 - Clin Exp Immunol. 1995 Sep;101(3):398-407
16200580 - Arthritis Rheum. 2005 Oct;52(10):3004-14
7521808 - Clin Exp Immunol. 1994 Sep;97(3):451-7
11094422 - Arthritis Res. 2000;2(2):126-31
12088413 - Cell Immunol. 2001 Dec 15;214(2):145-54
1642656 - Arthritis Rheum. 1992 Aug;35(8):905-13
11123349 - J Immunol. 2001 Jan 1;166(1):650-5
11432208 - Adv Immunol. 2001;78:57-110
15751074 - Arthritis Rheum. 2005 Mar;52(3):710-21
11673556 - J Immunol. 2001 Nov 1;167(9):5381-5
11368435 - Leukemia. 2001 May;15(5):752-6
1417131 - Ann Rheum Dis. 1992 Sep;51(9):1029-35
19500335 - Arthritis Res Ther. 2009;11(3):R84
11257159 - Rheumatology (Oxford). 2001 Feb;40(2):205-11
18177511 - Arthritis Res Ther. 2007;9(6):224
10975862 - J Immunol. 2000 Sep 15;165(6):3423-9
17306038 - Arthritis Res Ther. 2007;9(1):202
8552609 - Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):221-5
18722135 - Cytokine. 2008 Oct;44(1):1-8
10967023 - Int Immunol. 2000 Sep;12(9):1285-92
References_xml – volume: 15
  start-page: 752
  year: 2001
  ident: 2660_CR20
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2402107
– volume: 51
  start-page: 1029
  year: 1992
  ident: 2660_CR9
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.51.9.1029
– volume: 35
  start-page: 905
  year: 1992
  ident: 2660_CR31
  publication-title: Arthritis Rheum
  doi: 10.1002/art.1780350809
– volume: 165
  start-page: 6590
  year: 2000
  ident: 2660_CR28
  publication-title: J Immunol
  doi: 10.4049/jimmunol.165.11.6590
– volume: 397
  start-page: 263
  year: 1999
  ident: 2660_CR34
  publication-title: Nature
  doi: 10.1038/16717
– volume: 52
  start-page: 3004
  year: 2005
  ident: 2660_CR35
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21301
– volume: 214
  start-page: 145
  year: 2001
  ident: 2660_CR37
  publication-title: Cell Immunol
  doi: 10.1006/cimm.2001.1890
– volume: 101
  start-page: 398
  year: 1995
  ident: 2660_CR23
  publication-title: Clin Exp Immunol
  doi: 10.1111/j.1365-2249.1995.tb03126.x
– volume: 54
  start-page: 2793
  year: 2006
  ident: 2660_CR2
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22025
– volume: 12
  start-page: 121
  year: 2000
  ident: 2660_CR11
  publication-title: Immunity
  doi: 10.1016/S1074-7613(00)80165-X
– volume: 9
  start-page: 202
  year: 2007
  ident: 2660_CR3
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar2107
– volume: 167
  start-page: 5381
  year: 2001
  ident: 2660_CR38
  publication-title: J Immunol
  doi: 10.4049/jimmunol.167.9.5381
– volume: 2
  start-page: 126
  year: 2000
  ident: 2660_CR30
  publication-title: Arthritis Res
  doi: 10.1186/ar77
– volume: 78
  start-page: 57
  year: 2001
  ident: 2660_CR12
  publication-title: Adv Immunol
  doi: 10.1016/S0065-2776(01)78002-9
– volume: 97
  start-page: 451
  year: 1994
  ident: 2660_CR22
  publication-title: Clin Exp Immunol
  doi: 10.1111/j.1365-2249.1994.tb06109.x
– volume: 168
  start-page: 5333
  year: 2002
  ident: 2660_CR25
  publication-title: J Immunol
  doi: 10.4049/jimmunol.168.10.5333
– volume: 148
  start-page: 3296
  year: 1992
  ident: 2660_CR7
  publication-title: J Immunol
  doi: 10.4049/jimmunol.148.10.3296
– volume: 44
  start-page: 1
  year: 2008
  ident: 2660_CR13
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2008.06.017
– volume: 9
  start-page: 224
  year: 2007
  ident: 2660_CR4
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar2333
– volume: 25
  start-page: 361
  year: 2005
  ident: 2660_CR26
  publication-title: Rheumatol Int
  doi: 10.1007/s00296-004-0449-x
– volume: 9
  start-page: 205
  year: 2007
  ident: 2660_CR6
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar2125
– volume: 170
  start-page: 6320
  year: 2003
  ident: 2660_CR18
  publication-title: J Immunol
  doi: 10.4049/jimmunol.170.12.6320
– volume: 166
  start-page: 650
  year: 2001
  ident: 2660_CR29
  publication-title: J Immunol
  doi: 10.4049/jimmunol.166.1.650
– volume: 40
  start-page: 205
  year: 2001
  ident: 2660_CR1
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/40.2.205
– volume: 83
  start-page: 579
  year: 2003
  ident: 2660_CR24
  publication-title: Lab Invest
  doi: 10.1097/01.LAB.0000062854.30195.52
– volume: 52
  start-page: 710
  year: 2005
  ident: 2660_CR14
  publication-title: Arthritis Rheum
  doi: 10.1002/art.20932
– volume: 11
  start-page: R84
  year: 2009
  ident: 2660_CR21
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar2718
– volume: 9
  start-page: 219
  year: 2007
  ident: 2660_CR5
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar2200
– volume: 343
  start-page: 1594
  year: 2000
  ident: 2660_CR33
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200011303432202
– volume: 172
  start-page: 3422
  year: 2004
  ident: 2660_CR10
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.6.3422
– volume: 95
  start-page: 627
  year: 2000
  ident: 2660_CR19
  publication-title: Blood
  doi: 10.1182/blood.V95.2.627
– volume: 31
  start-page: 315
  year: 1988
  ident: 2660_CR16
  publication-title: Arthritis Rheum
  doi: 10.1002/art.1780310302
– volume: 12
  start-page: 1285
  year: 2000
  ident: 2660_CR17
  publication-title: Int Immunol
  doi: 10.1093/intimm/12.9.1285
– volume: 164
  start-page: 5010
  year: 2000
  ident: 2660_CR36
  publication-title: J Immunol
  doi: 10.4049/jimmunol.164.10.5010
– volume: 165
  start-page: 3423
  year: 2000
  ident: 2660_CR27
  publication-title: J Immunol
  doi: 10.4049/jimmunol.165.6.3423
– volume: 93
  start-page: 221
  year: 1996
  ident: 2660_CR32
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.93.1.221
– volume: 20
  start-page: 929
  year: 2006
  ident: 2660_CR15
  publication-title: Best Pract Res Clin Rheumatol
  doi: 10.1016/j.berh.2006.06.001
– volume: 173
  start-page: 487
  year: 1991
  ident: 2660_CR8
  publication-title: J Exp Med
  doi: 10.1084/jem.173.2.487
– reference: 15751074 - Arthritis Rheum. 2005 Mar;52(3):710-21
– reference: 16947627 - Arthritis Rheum. 2006 Sep;54(9):2793-806
– reference: 15004722 - Rheumatol Int. 2005 Jun;25(5):361-7
– reference: 11432208 - Adv Immunol. 2001;78:57-110
– reference: 7521808 - Clin Exp Immunol. 1994 Sep;97(3):451-7
– reference: 9930702 - Nature. 1999 Jan 21;397(6716):263-6
– reference: 1417131 - Ann Rheum Dis. 1992 Sep;51(9):1029-35
– reference: 16980215 - Best Pract Res Clin Rheumatol. 2006 Oct;20(5):929-39
– reference: 18177511 - Arthritis Res Ther. 2007;9(6):224
– reference: 1642656 - Arthritis Rheum. 1992 Aug;35(8):905-13
– reference: 11368435 - Leukemia. 2001 May;15(5):752-6
– reference: 11994492 - J Immunol. 2002 May 15;168(10):5333-41
– reference: 17850683 - Arthritis Res Ther. 2007;9(4):219
– reference: 10799853 - J Immunol. 2000 May 15;164(10):5010-4
– reference: 11257159 - Rheumatology (Oxford). 2001 Feb;40(2):205-11
– reference: 12088413 - Cell Immunol. 2001 Dec 15;214(2):145-54
– reference: 8552609 - Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):221-5
– reference: 16200580 - Arthritis Rheum. 2005 Oct;52(10):3004-14
– reference: 11094422 - Arthritis Res. 2000;2(2):126-31
– reference: 12794165 - J Immunol. 2003 Jun 15;170(12):6320-8
– reference: 18722135 - Cytokine. 2008 Oct;44(1):1-8
– reference: 10967023 - Int Immunol. 2000 Sep;12(9):1285-92
– reference: 17306038 - Arthritis Res Ther. 2007;9(1):202
– reference: 10975862 - J Immunol. 2000 Sep 15;165(6):3423-9
– reference: 1703209 - J Exp Med. 1991 Feb 1;173(2):487-9
– reference: 15004141 - J Immunol. 2004 Mar 15;172(6):3422-7
– reference: 19500335 - Arthritis Res Ther. 2009;11(3):R84
– reference: 17349064 - Arthritis Res Ther. 2007;9(2):205
– reference: 11123349 - J Immunol. 2001 Jan 1;166(1):650-5
– reference: 11086103 - J Immunol. 2000 Dec 1;165(11):6590-8
– reference: 12695561 - Lab Invest. 2003 Apr;83(4):579-88
– reference: 7545093 - Clin Exp Immunol. 1995 Sep;101(3):398-407
– reference: 10627472 - Blood. 2000 Jan 15;95(2):627-32
– reference: 11673556 - J Immunol. 2001 Nov 1;167(9):5381-5
– reference: 1578151 - J Immunol. 1992 May 15;148(10):3296-301
– reference: 11096166 - N Engl J Med. 2000 Nov 30;343(22):1594-602
– reference: 10714678 - Immunity. 2000 Feb;12(2):121-7
– reference: 3358796 - Arthritis Rheum. 1988 Mar;31(3):315-24
SSID ssj0022924
Score 2.2528431
Snippet Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to...
Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to the...
Introduction Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to...
INTRODUCTION: Accumulation of B cells in the rheumatoid arthritis (RA) synovium has been reported, and it has been thought that these cells might contribute to...
SourceID pubmedcentral
biomedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage R149
SubjectTerms Antigens, CD - biosynthesis
Arthritis, Rheumatoid - immunology
Arthritis, Rheumatoid - metabolism
B cells
B-Cell Activation Factor Receptor - biosynthesis
B-Lymphocytes - immunology
B-Lymphocytes - metabolism
Cell Proliferation
Chemokine receptors
Chemokines
Chemotaxis, Leukocyte - immunology
Development and progression
Enzyme-Linked Immunosorbent Assay
Flow Cytometry
Genetic aspects
Health aspects
Humans
Inducible T-Cell Co-Stimulator Ligand
Lymphocyte Activation - immunology
Medicine
Medicine & Public Health
Orthopedics
Receptors, Chemokine - biosynthesis
Receptors, Chemokine - immunology
Research Article
Rheumatoid arthritis
Rheumatology
Transmembrane Activator and CAML Interactor Protein - biosynthesis
Tumor Necrosis Factor-alpha - biosynthesis
Title Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis
URI https://link.springer.com/article/10.1186/ar2823
https://www.ncbi.nlm.nih.gov/pubmed/19804625
https://www.proquest.com/docview/217489724
https://www.proquest.com/docview/21273606
https://www.proquest.com/docview/734157562
http://dx.doi.org/10.1186/ar2823
https://pubmed.ncbi.nlm.nih.gov/PMC2787286
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1La9wwEB6aFEovpekrbpqtDi09mdqyLMu9bZeEUEhPXcjNyLLcNQ122Af0F-R3Z0aWd2tDyc1GY1t4HvrmoRHAp1SnVZmVKkyzJAuF1lWoUy7CWNeqMtxGtQu4Xf-UV0vx4ya98fGOzVDtPqQknaV2aq3kV71G7yA5gqcp-uukgks-37tWHN0If3LQgXayh_12tPRMDfA_K9C0OnKSInUrz-VLeOEhI5v3PD6BJ7Z9Bc-ufVL8NdzTpv_uD14zNF_2Dr1oZv_6AteW6bZitHr1QT_mCzhYVzMzPId3LfvOKIi_-caaQ5E5a1qGCJHRucXdbzKLjXtyvbI7hLpdUzEUvZVrjPQGlpcXvxZXoT9eISwRM23DRIpYWVyPFKUmRWnQ1ERlpfPIylxp6mtvtUgya_JaaRGXxkQ2kzLiOql1kiVv4bjtWnsKzKBiV9KitTC5qJM6r2VcWgSHcalzNCEB8BEniru-lUZBza3HI8jyomdfAJ8HdhXGNyynczNuC-e4KLmn-7inG947pfhC3C5IZ_ENRvutBzh56n5VzNHvRdwqpAzgbBCIwivzpiCvTeUZF_il_ShqIXFFt7bbEQnCQPQFA2D_ocgQLiA0ljyAd718HSabK9oinAaQjSRv9JfGI22zcq3AOdpbruizg4wepj3-B-8fJzmD532ujAJMH-B4u97Zc4Rc23IGRwu5mLmAxcxp3gMDiTLn
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB7BVgIuVXmHAvUBxCkicRzH6W2pqJal2wut1JtlO043okqqfUj8An4348TZJZEQt0SeJFbm4W8eHgN8SFVa6EyLMM2SLGRKFaFKKQtjVYrCUBuVbcBtccln12x-k974eMe6r3bvU5KtpW7VWvDPaoXeQfIQDgQiEDaBg-l0_mO-c64oOhL-7KA99WgX-91g8Rmb4L_WoHF95ChJ2q4950dw6EEjmXZcfgoPbP0MHi18Wvw5_Hbb_pufeE3QgNl79KOJ_eVLXGui6oK49asL-xFfwkGakpj-ObyryRfiwvjrU1Lty8xJVRPEiMSdXNzcOsNYtU-ulnaLYLepCoLCt2xbI72A6_OvV2ez0B-wEGpETZsw4SwWFlck4ZKTTBs0NpEuVB5ZngvlOttbxZLMmrwUisXamMhmnEdUJaVKsuQlTOqmtq-BGFTtglu0FyZnZVLmJY-1RXgYa5WjEQmADjgh77tmGtK1tx6OINNlx74APvbsksa3LHcnZ9zJ1nURfEd3sqPr3zum-OS4LZ3W4huM8psPcPKu_5WcoueLyJVxHsBxLxDSq_NaOr9N5Bll-KXdKOqh44qqbbN1JAgE0RsMgPyDIkPAgOCY0wBedfK1n2wu3CbhNIBsIHmDvzQcqatl2wycosWlwn22l9H9tIf_4M3_SU7g8exqcSEvvl1-P4YnXebMhZvewmSz2tp3CMA2-r3XvT839TVY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB5BkSouFW9CgfoA4hQ1D8dxuJW2q_JoxYFKvVmO47BRK2e1D4lfwO9mJnF2SSTELZEniZXxzHzjeRjgXaazqsxLGWZ5modc6yrUWcLDWNeyMomN6m7D7fJKXFzzLzfZjS8KWw3Z7kNIsq9poC5Nbn28qOpexKU41kv0FNL78ICTuaMQrTjdulkJuhT-FKEd7aSe_W5khqbK-C9rNM2UnIRLOys0ewQHHj6yk57fj-GedU9g_9IHyJ_Cb2oA0N7iNUNVZhfoUTP7yye7OqZdxciS9RuAzCdzsLZmZngO7xz7xGhDf_WRNbuEc9Y4hmiR0RnG7U9SkU335HJuNwh726ZiuAznXZOkZ3A9O_9xehH6oxbCEvHTOkwFj6VF2yQpTMlLg2onKitdRFYUUlOPe6t5mltT1FLzuDQmsrkQUaLTWqd5-hz2XOvsS2AGhbwSFjWHKXid1kUt4tIiUIxLXaA6CSAZcUIt-rYaihpdj0eQ_apnXwDvB3Yp45uX0xkad6pzYqTY0h1t6Yb3Tik-ELcVyS--wWhfhoCTp05Y6gR9YMSwXIgADocFobxgrxR5cLLIE45f2o6iRBJXtLPthkgQEqJfGAD7B0WO0AFhskgCeNGvr91kC0nlwlkA-Wjljf7SeMQ1864teIK6N5H02WGN7qY9_gev_k9yBPvfz2bq2-err4fwsA-h0b7Ta9hbLzf2DSKxdfm2E7w_heM4Lg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chemokine+receptor+expression+and+functional+effects+of+chemokines+on+B+cells%3A+implication+in+the+pathogenesis+of+rheumatoid+arthritis&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Nanki%2C+Toshihiro&rft.au=Takada%2C+Kazuki&rft.au=Komano%2C+Yukiko&rft.au=Morio%2C+Tomohiro&rft.date=2009-01-01&rft.pub=BioMed+Central+Ltd&rft.issn=1478-6354&rft.eissn=1478-6362&rft.volume=11&rft.issue=5&rft.spage=R149&rft.epage=R149&rft_id=info:doi/10.1186%2Far2823&rft.externalDBID=n%2Fa&rft.externalDocID=oai_biomedcentral_com_ar2823
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6354&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6354&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6354&client=summon